WO1993014786A1 - Composition et procede anticonceptionnels ou de sterilisation pour animaux - Google Patents

Composition et procede anticonceptionnels ou de sterilisation pour animaux Download PDF

Info

Publication number
WO1993014786A1
WO1993014786A1 PCT/US1993/001038 US9301038W WO9314786A1 WO 1993014786 A1 WO1993014786 A1 WO 1993014786A1 US 9301038 W US9301038 W US 9301038W WO 9314786 A1 WO9314786 A1 WO 9314786A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
zona pellucida
zpds
animal
recombinant
Prior art date
Application number
PCT/US1993/001038
Other languages
English (en)
Inventor
Richard Arnold Bowen
Original Assignee
Colorado State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorado State University Research Foundation filed Critical Colorado State University Research Foundation
Publication of WO1993014786A1 publication Critical patent/WO1993014786A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Definitions

  • the present invention is related to protein-based contraceptive vaccines and methods for their use. More particularly, the invention relates to recombinant porcine zona pellucida proteins and their use as a contraceptive vaccine.
  • the zona pellucida is a glycoprotein coat surrounding the eggs of mammals.
  • Sperm normally attach to the zona pellucida via a sperm receptor located on the zona pellucida. After attachment, a sperm releases enzymes enabling it to penetrate the zona pellucida and to enter and fertilize the egg.
  • a contraceptive vaccine which need be administered only once or a few times, is much more convenient than current modes of contraception. Use of contraceptive vaccines to reversibly or permanently sterilize animals is an attractive and economic alternative to surgical castration.
  • a contraceptive vaccine also has advantages over hormone or hormone antagonist treatments which may cause undesirable side effects, such as cancer.
  • a contraceptive vaccine is preferable to passive immunization techniques in which polyclonal or monoclonal antibodies are administered.
  • Techniques of passive immunization are described in U.S Patent No. 3,992,520 by Gwatkin, issued Nov. 16, 1976; U.S. Patent No. 4,996,297 by Dunbar, issued Feb. 26, 1991; Henderson et al., J. Reprod. Fert. 83:325-343, 1988.
  • Antibodies function for only a limited time period in the body and must, therefore, be administered frequently. Repeated administration of antibodies often causes immunized individuals to mount an immune response against the antibodies themselves, rendering the treatments ineffective.
  • Anti-idiotypic antibodies that contain images of zona pellucida epitopes such as those described in U.S. Patent 4,795,634 by Grimes et al., Jan. 3, 1989, are difficult and expensive to produce. Moreover, individuals immunized with such anti-idiotypic antibodies may mount immune responses against regions of the anti-idiotypic antibody other than the zona pellucida-like domain.
  • a source of zona pellucida proteins having the required specificity, efficacy, and absence of contaminants required for commercial applications are not known to the inventor. Purification of zona pellucida proteins has been hampered by the proteins' heterogenous glycosylation patterns and multiple disulfide bonds. Moreover, utilizing natural sources of zona pellucida proteins to produce vaccines is impractical because there are simply not enough ovaries available for commercial scale development. Although attempts have been made to purify porcine zona pellucida proteins, it is still unclear how many distinct porcine zona pellucida proteins there are. For example, Hedrick and Wardrip (Anal. Biochem.
  • ZP4 and ZP2 may be proteolytic products of ZPl (Japanese Patent JP 63,150,299 to Toa Nenryo Kogyo KK, 1988; Hedrick and Wardrip, Dev. Biol. 121:478-488, 1987).
  • Partially purified preparations of porcine zona pellucida proteins have been tested for their ability to induce the formation of zona pellucida-specific antibodies and to temporarily prevent conception in rabbits, dogs, mares, and several kinds of monkeys (e.g., Shivers et al., J. Am. Anim. Hosp. Assn. 17:823-828, 1981; Mahi-Brown et al., Biol.
  • the present invention provides zona pellucida protein- based contraceptive vaccines and methods to use zona pellucida protein vaccines to prevent conception in animals. Contraception may be either reversible (i.e., temporary) or permanent (i.e., rendering an animal sterile) depending on the manner in which the vaccine is administered.
  • the present invention includes recombinant porcine zona pellucida proteins, DNA sequences encoding those proteins, recombinant methods to produce those proteins, and methods to produce vaccines comprising one or more of those proteins.
  • the present invention also includes methods to use one or more zona pellucida proteins to induce the production of zona pellucida-specific antibodies in a vaccinated animal and to detect the presence of zona pellucida-specific antibodies in a sample of a bodily fluid.
  • Figure 1 illustrates the relative locations of porcine zona pellucida DNA sequences ZPDS.1711, ZPDS.535, ZPDS.411, and ZPDS.1176 on ZPDS.2500.
  • FIG. 2 illustrates the DNA and deduced amino acid sequences of ZPDS.1711.
  • FIG. 3 illustrates the DNA and deduced amino acid sequences of ZPDS.311.
  • Figure 4 illustrates the DNA and deduced amino acid sequences of ZPDS.447.
  • Figure 5 is a schematic drawing of recombinant molecule pGEX2T:ZPDS.411.
  • Figure 6 is a schematic drawing of recombinant molecule pVL1393:ZPDS.1711.
  • One aspect of the present invention involves the production of recombinant porcine zona pellucida proteins using nucleic acid sequences that encode at least a portion of a zona pellucida protein capable of preventing conception when administered to an animal.
  • nucleic acid sequences that encode at least a portion of a zona pellucida protein capable of preventing conception when administered to an animal.
  • a portion of a zona pellucida protein refers to a segment of a zona pellucida protein ranging in size from at least about seven amino acids to a full-length protein that is capable of preventing conception.
  • the nucleic acid sequences of the present invention can be either RNA or DNA and can be used to produce recombinant zona pellucida proteins.
  • a "zona pellucida DNA sequence" refers to a DNA sequence corresponding to at least a portion of a zona pellucida gene that is sufficient to encode a protein capable of preventing conception when administered to an animal. Zona pellucida DNA sequences can be isolated from natural sources or can be synthesized chemically.
  • the present invention includes zona pellucida DNA sequences that encode full-length zona pellucida proteins as well as DNA sequences that contain nucleotide deletions, additions, and/or substitutions which do not interfere with a sequence's ability to encode a protein capable of preventing conception in an animal.
  • Preferred zona pellucida DNA sequences encode recombinant zona pellucida proteins that share significant homology with porcine zona pellucida proteins.
  • a "recombinant zona pellucida protein,” also called a “recombinant protein,” refers to a protein obtained using the techniques of recombinant DNA technology.
  • the minimal size of a recombinant zona pellucida protein is the shortest segment of amino acids required to induce the formation of antibodies capable of preventing conception. While not bound by theory, it is believed that a protein segment at least about seven amino acids long is required to elicit antibody formation.
  • a recombinant protein can be produced in a host in which at least one zona pellucida DNA sequence has been inserted in a manner such that the host is capable of expressing said sequence (i.e., of producing a protein by transcribing and translating the inserted DNA sequence) .
  • a recombinant protein can also be produced by chemically synthesizing a protein corresponding to a zona pellucida DNA sequence, or by incubating a nucleic acid sequence encoding at least a portion of a zona pellucida protein with the appropriate enzymes and substrates to express the protein.
  • the zona pellucida DNA sequences of the present invention can be isolated from any species that contains DNA sequences encoding a protein corresponding to a zona pellucida protein capable of inducing contraception in an animal.
  • Preferred species from which to isolate zona pellucida DNA sequences are mammals, and preferred mammals from which to isolate zona pellucida DNA sequences are pigs.
  • Methods to isolate the zona pellucida DNA sequences of the present invention include, but are not limited to, screening a complementary DNA (cDNA) or genomic DNA library with at least one oligo- or polynucleotide able to bind to zona pellucida DNA sequences; screening a cDNA expression library with a preparation of zona pellucida-specific antibodies or other compounds able to bind to the zona pellucida; using polymerase chain reaction amplification to make multiple copies of zona pellucida DNA sequences directly from nucleic acids; and chemically synthesizing zona pellucida DNA sequences.
  • cDNA complementary DNA
  • genomic DNA library with at least one oligo- or polynucleotide able to bind to zona pellucida DNA sequences
  • screening a cDNA expression library with a preparation of zona pellucida-specific antibodies or other compounds able to bind to the zona pellucida using polymerase chain reaction amplification to make multiple copies of
  • the preferred source of messenger RNA (mRNA) from which to construct a cDNA library is the ovary because the ovary is the only known tissue which expresses zona pellucida genes.
  • a most preferred source of mRNA is an ovary isolated from a pig that has not yet undergone puberty, preferably a pig that is three to five months old. While not being bound by theory, it is believed that zona pellucida proteins are expressed at high levels during this phase of pig development.
  • RNA is isolated from ovaries, and polyadenylated RNA (which includes mRNA) is purified from total RNA using oligo-dT cellulose chromatography.
  • the isolated polyadenylated RNA is used as a template to prepare cDNA in a two step process. First, reverse transcriptase and polyadenylated RNA are combined with oligo-dT, random primers, or a mixture thereof, to obtain a DNA copy of the RNA.
  • DNA polymerase and RNAse H are added to the DNA copy to produce a second DNA strand.
  • the resulting cDNA sequences are a complex mixture of DNA sequences including those that encode at least a portion of proteins expressed in the ovary, such as zona pellucida proteins.
  • a "vector” is a nucleic acid sequence that is capable of being transformed into a host and is capable of replicating in said host.
  • a vector usually has one or more sites at which DNA sequences can be inserted without disrupting a vector's ability to transform or replicate.
  • Vectors often have markers suitable for identification of hosts transformed with said vectors.
  • Vectors include, but are not limited to plasmids, cosmids, phagemids, bacteriophage, and viruses.
  • transformation covers any process by which a nucleic acid is inserted into a cell, wherein the cell may remain unicellular or may grow into a tissue or multicellular organism. Transformation includes, but is not limited to, techniques such as transfection, electroporation, protoplast fusion, and the process by which transgenic animals are produced.
  • the preferred cloning vector of the present invention is an E. coli bacteriophage expression vector called lambda gtll, and the preferred host is E. coli.
  • EcoRI linkers are added to the ends of porcine ovary cDNA sequences and the resultant EcoRI-linkered cDNA sequences are inserted into lambda gtll at the EcoRI restriction endonuclease site.
  • An ovary cDNA library consists of numerous clones containing a variety of cDNA sequences. Only a few of the clones contain sequences corresponding to zona pellucida DNA sequences.
  • a mammalian ovary cDNA library preferably from a pig, is screened to identify clones containing zona pellucida DNA sequences.
  • cDNA or genomic DNA libraries can be screened with oligo- and polynucleotide probes that are sufficiently similar to zona pellucida DNA sequences to be able to hybridize to nucleic acids containing zona pellucida DNA sequences.
  • the sequences of the oligo- or polynucleotides can be derived from partial zona pellucida protein amino acid sequences and may be either codon-biased or degenerate.
  • oligonucleotides or polynucleotides can be either RNA- or DNA-based.
  • Zona pellucida DNA sequences produced in accordance with the present invention can be used as probes to identify additional zona pellucida DNA sequences. Methods to identify specific DNA sequences using nucleic acid probes are described in detail in Sambrook et al. (ibid.).
  • zona pellucida-specific antibodies or other compounds able to bind specifically to the zona pellucida are used to screen cDNA expression libraries for clones containing zona pellucida genes.
  • zona pellucida-specific antibodies refer to antibodies able to recognize and bind to zona pellucida proteins but are not able to effectively bind to other proteins.
  • cDNA expression libraries are libraries which are incubated under conditions that induce the expression of proteins encoded by DNA sequences of the cDNA library.
  • a cDNA expression library is plated onto a solidified medium such that individual colonies or plaques can be identified.
  • the solidified medium promotes growth and production of proteins encoded by the cDNA sequences.
  • the production of proteins is induced after colonies or plaques have formed.
  • the produced proteins are transferred onto a filter and exposed to zona pellucida-specific antibodies under conditions that promote binding between the antibodies and recombinant zona pellucida proteins.
  • zona pellucida-specific antibodies that are labeled may be used.
  • a second antibody which is labeled and which binds to the zona pellucida- specific antibodies is added under conditions that promote binding of the second antibody to zona pellucida-specific antibodies already bound to recombinant zona pellucida proteins.
  • Antibodies may be labeled in a variety of ways, including, but not limited to, the addition of radioactive, enzymatic, or fluorescent labels. Colonies or plaques producing proteins capable of binding to zona pellucida- specific antibodies may be identified by autoradiography or visual inspection and isolated. If necessary, such colonies or plaques may be replated and rescreened until single isolates are obtained.
  • Antibodies which can be used to identify colonies containing zona pellucida DNA sequences include monoclonal and polyclonal antibodies and fragments thereof able to bind to zona pellucida proteins.
  • a polyclonal antibody preparation obtained by immunizing an animal with solubilized mammalian, preferably porcine, zonae pellucidae is used.
  • Zonae pellucidae may be isolated from ovaries and then solubilized by heating in an aqueous medium. Solubilized zonae pellucidae should contain all zona pellucida proteins and thus, should induce an animal to produce a variety of antibodies capable of binding to most, if not all, zona pellucida proteins.
  • Antibodies obtained by immunizing an animal with solubilized porcine zonae pellucidae are referred to as "antibodies specific for a solubilized porcine zona pellucida.”
  • porcine zona pellucida DNA sequences are identified by screening a porcine ovary cDNA expression library with rabbit polyclonal antibodies specific for a solubilized porcine zona pellucida.
  • the present invention includes certain DNA sequences which may be used to identify additional zona pellucida- containing DNA sequences and/or to express proteins capable of sterilizing or otherwise preventing conception in an animal.
  • Full-length or hybrid zona pellucida genes may be obtained by joining two or more isolated or synthetic zona pellucida DNA sequences together.
  • a zona pellucida DNA sequence of about 2500 base pairs (bp) was isolated from a porcine ovary cDNA expression library which encodes a protein capable of binding to zona pellucida- specific antibodies.
  • the zona pellucida DNA sequence of about 2500-bp is composed of 3 EcoRI fragments of about 535 bp, about 1176 bp, and about 800 bp.
  • ZPDS.1711 is composed of the EcoRI fragment of about 535 bp, called ZPDS.535, joined to the EcoRI fragment of about 1176 bp, called ZPDS.1176.
  • ZPDS.411 is the Hindi-EcoRI fragment of about 411 bp contained within ZPDS.535.
  • ZPDS.2500 encodes 305 amino acids of a porcine zona pellucida protein called rZPP.305 (see Figure 2).
  • the coding sequence is contained within ZPDS.1711.
  • the protein encoded by ZPDS.2500 does not share significant homology with reported DNA sequences encoding mouse ZP2 (Liang et al., Mol. Cell. Biol. 10:1507-1515, 1990), mouse ZP3
  • ZPDS.2500 encodes a portion of porcine zona pellucida protein ZP2. It has been found that adminis ⁇ tration of the recombinant zona pellucida protein encoded by ZPDS.411 to rabbits induces the production of zona pellucida-specific antibodies.
  • the present invention includes two other distinct zona pellucida DNA sequences that encode proteins that bind to antibodies specific for solubilized porcine zona pellucida.
  • ZPDS.311 is an EcoRI fragment of about 311 bp that is capable of encoding a recombinant zona pellucida protein of about 103 amino acids (rZPP.103).
  • ZPDS.447 is an EcoRI fragment of about 447 bp capable of encoding a recombinant zona pellucida protein of about 149 amino acids, called rZPP.149 ( Figure 4).
  • rZPP.149 a recombinant zona pellucida protein of about 149 amino acids
  • Figure 4 Neither ZPDS.311 nor ZPDS.447 share significant homology with other zona pellucida proteins.
  • ZPDS.311 and ZPDS.447 do not hybridize to ZPDS.2500, nor do they hybridize to each other, suggesting that the three sequences represent distinct zona pellucida DNA sequences.
  • Another aspect of the present invention involves the use of zona pellucida DNA sequences to produce recombinant proteins that are capable of preventing conception. At least one zona pellucida DNA sequence is transformed into a host in a manner such that the transformed host is capable of expressing a recombinant zona pellucida protein(s) encoded by said DNA sequence(s) .
  • recombinant molecules are produced which comprise zona pellucida nucleic acid sequences, preferably zona pellucida DNA sequences, operatively linked to expression vectors.
  • a suitable expression vector comprises a nucleic acid sequence that is capable of inserting a zona pellucida nucleic acid sequence, preferably a zona pellucida DNA sequence, into a host and of directing transcription and translation of that sequence within the host.
  • Expression vectors of the present invention include both prokaryotic and eukaryotic vectors including, but not limited to, those that direct gene expression in bacteria, yeast, fungi, animals, insects, and plants.
  • Expression vectors include, but are not limited to, viruses and plasmids that contain regulatory sequences that control the expression of a gene. Examples of such regulatory sequences include, but are not limited to, the regulatory sequences of tac. lac, trp.
  • Expression vectors of the present invention may also contain secretory signals to enable an expressed zona pellucida protein to be secreted from its host cell or may contain fusion sequences which lead to the expression of inserted zona pellucida DNA sequences as a fusion protein.
  • Eukaryotic recombinant molecules may include intervening and/or untranslated sequences surrounding and/or within zona pellucida DNA sequences.
  • Preferred expression vectors include bacterial, yeast, and insect vectors. Particularly preferred expression vectors are those that function in E . coli or in insect cells.
  • a most preferred E. coli vector is pGEX-2T (available from Pharmacia) which contains tac regulatory sequences and which leads to the expression of cDNA sequences as part of a fusion protein with the carboxyl terminus of glutathione-S-transferase (GST) from Schistosoma iaponicum.
  • Most preferred insect vectors are baculovirus (Autographa californica nuclear polyhedrosis virus) vectors, such as pVL1393 from InVitrogen.
  • Recombinant molecules useful in the present invention include, but are not limited to, zona pellucida nucleic acid sequences inserted into expression vectors capable of being expressed in bacteria, yeast, fungi, insects, animals or plants.
  • Preferred recombinant molecules include bacterial and insect cell expression vectors containing one or more zona pellucida DNA sequences.
  • zona pellucida DNA sequence ZPDS.411 is operatively linked to bacterial expression vector pGEX-2T to form recombinant molecule pGEX2T:ZPDS.411 (see Figure 5).
  • zona pellucida DNA sequence ZPDS.1711 is operatively linked to baculovirus vector pVL1393 to form recombinant molecule pVL1393:ZPDS.1711 (see Figure 6).
  • the present invention also includes a method to transform prokaryotic or eukaryotic hosts with recombinant molecules, as well as the transformed hosts themselves. As discussed above, transformation can be accomplished by any process in which a recombinant molecule is inserted into a host, wherein the host may remain unicellular or may grow into a tissue or multicellular organism.
  • Preferred hosts include bacteria, yeast, fungi, insects, insect cells, animals, animal cells, plants, and plant cells. In the practice of the present invention, the most preferred bacterial host is E. coli. and the most preferred insect cell host is Spodoptera frugiperda.
  • Native zona pellucida proteins are highly glycosylated and it is believed that important zona pellucida antigenic determinants are carbohydrates.
  • enzymatically or chemically deglycosylated zona pellucida proteins elicit the production of antibodies with different characteristics than those induced by native zona pellucida proteins. It is as yet unknown what type of responses are elicited by totally nonglycosylated proteins, such as would be produced by bacteria.
  • Insect cells exhibit a somewhat different glycosylation pattern than do mammalian cells with respect to sugar composition, chain length and complexity. Without being bound by theory, it is believed that carbohydrate differences may enhance mammalian immune responses to insect cell-derived recombinant antigens.
  • eukaryotic cells are used as hosts due to their ability to glycosylate proteins.
  • Insect cells are preferred as hosts because they are able to produce large quantities of glycosylated recombinant zona pellucida proteins.
  • a recombinant molecule containing at least one zona pellucida DNA sequence may be transformed into a host. Such a transformed host can then be cultured in an effective medium to produce recombinant protein(s) encoded by the zona pellucida DNA sequence(s) .
  • the recombinant protein(s) can subsequently be formulated into a contraceptive vaccine.
  • zona pellucida DNA sequence ZPDS.1711 is inserted into the E. coli expression vector pGEX-2T to produce recombinant molecule pGEX2T:ZPDS.1711.
  • Recombinant molecule pGEX2T:ZPDS.1711 is transformed into E. coli. producing transformed host E. coli pGEX2T:ZPDS.1711.
  • zona pellucida DNA sequence ZPDS.1711 is inserted into baculovirus vector pVL1393 to produce recombinant molecule pVL1393:ZPDS.1711.
  • Recombinant molecule pVL1393:ZPDS.1711 is transformed into Spodoptera frugiperda insect cells, producing transformed host S_. frugiperda pVL1393:ZPDS.1711.
  • major influences on gene expression are achieved by manipulating, for example, the number of copies of the gene within the cell, the efficiency with which those gene copies are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications.
  • Recombinant techniques useful for increasing the expression of zona pellucida DNA sequences include, but are not limited to, insertion of zona pellucida DNA sequences into high-copy number plasmids, insertion of zona pellucida DNA sequences into one or more host chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers) , substitutions or modifications of translational control signals (e.g., riboso e binding sites, Shine- Delgarno sequences) , modification of zona pellucida DNA sequences to correspond to the codon usage of the host, expression of zona pellucida proteins as fusion proteins, deletion of sequences that destabilize transcripts, insertion of intervening sequences into zona pellucida DNA sequences expressed in eukaryotic cells, and use of control signals that temporally separate transformed host cell growth from zona pellucida protein production during fermentations.
  • the economics of production may be improved by expressing more than one zona pellucida protein in a given host.
  • the activity of the expressed zona pellucida protein may be improved by fragmenting, modifying, or derivatizing zona pellucida DNA sequences or recombinant zona pellucida proteins using standard techniques.
  • an "effective medium” refers to any medium in which a transformed host can produce recombinant zona pellucida proteins.
  • An effective medium is typically an aqueous medium comprising assimilable carbohydrate, nitrogen, and phosphate sources, as well as appropriate salts, minerals, metals and other nutrients, such as vitamins.
  • the medium may comprise complex nutrients or may be a defined minimal medium.
  • Culturing can be conducted in conventional fermentation bioreactors, which include, but are not limited to, batch, fed-batch and continuous fermenters, as well as transformed plants and animals.
  • a single transformed host is cultured at a time.
  • Culturing is carried out at a temperature, pH, and oxygen content appropriate for the host.
  • culturing comprises two steps. Hosts are initially grown in a medium effective to promote growth of the hosts. After the host has reached a desired cell density, a second medium is introduced that promotes production of recombinant zona pellucida proteins.
  • the second medium can include a compound that induces expression of the recombinant proteins.
  • expression of a zona pellucida DNA sequence under the control of E. coli lac regulatory sequences can be induced by the addition of, for example, lactose or isopropyl-beta- D-thiogalactopyranoside (IPTG) .
  • IPTG isopropyl-beta- D-thiogalactopyranoside
  • insect cell hosts transformed with at least one zona pellucida DNA sequence are grown in an effective medium at a temperature from about 32°C to about 45°C, and at a pH from about pH 6.8 to about pH 7.4.
  • insect cell hosts transformed with at least one zona pellucida DNA sequence are cultured in an effective medium at a temperature from about 25°C to about 30°C, preferably from about 26°C to about 28°C, and at a pH from about pH 6.1 to about pH 6.5, preferably from about pH 6.3 to about pH 6.4.
  • resultant recombinant zona pellucida proteins may either (1) remain within the transformed host cell, (2) be secreted into the fermentation medium, (3) be secreted into a space between two cellular membranes, such as the periplasmic space in E. coli. or (4) be retained on the outer surface of a cell or viral membrane.
  • Recombinant zona pellucida proteins may be recovered using a combination of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, and hydrophobic interaction chromatography.
  • recombinant zona pellucida proteins are recovered in "substantially pure” form.
  • substantially pure refers to a purity that allows for the effective use of the protein as a vaccine or diagnostic.
  • a contraceptive vaccine for animals for example, should exhibit no substantial toxicity and should be capable of stimulating the production of antibodies in a vaccinated animal. It is within the scope of the present invention to recover recombinant zona pellucida proteins having a purity of at least about 90%.
  • the recombinant zona pellucida proteins and zona pellucida DNA sequences of the present invention can also be used to derive additional zona pellucida DNA sequences and zona pellucida proteins, such as full-length cDNA sequences or zona pellucida proteins and DNA sequences of other species.
  • recombinant zona pellucida proteins to monitor the ability of a vaccinated animal to produce antibodies specific to the zona pellucida or to identify females who may be infertile because they produce antibodies that bind to their own zonae pellucidae.
  • the recombinant proteins can be labeled, for example with a radioactive, enzymatic, or fluorescent label, and mixed with a bodily fluid sample, such as a serum or urine sample, which may contain zona pellucida-specific antibodies in a medium, such as a buffer, which allows the antibodies to bind to the labeled recombinant protein.
  • the amount of recombinant protein added to the sample should be sufficient to allow substantially all zona pellucida- specific antibodies present in the sample to bind to said recombinant protein. Complexes can be separated from unbound recombinant protein and analyzed to determine the amount of zona pellucida-specific antibodies present in the sample.
  • Antibodies produced by vaccination of an animal with the recombinant proteins of the present invention can also be used as a passive contraceptive vaccine or can be used to recover zona pellucida proteins, including recombinant zona pellucida proteins, from a mixture of proteins and other contaminants.
  • the present invention includes a safe and cost- effective contraceptive vaccine that, depending on its mode of administration, provides reversible or permanent contraception.
  • a vaccine of the present invention contains at least one of the proteins, or portions thereof, that make up the zona pellucida.
  • the zona pellucida protein, or portion thereof can be recombinant, isolated from a natural source, or chemically synthesized.
  • Vaccines of the present invention are capable of triggering the production of zona pellucida-specific antibodies that bind to the zona pellucida, thereby preventing sperm attachment.
  • a vaccine of the present invention can cause disruption of ovarian function, leading to sterility.
  • Vaccines of the present invention can be administered to any animal, including humans, in which it is efficacious.
  • Preferred animals are mammals, which are known to have zonae pellucidae surrounding their eggs. Due to the wide degree of structural and functional diversity among zona pellucida proteins of different species, it cannot be assumed that a vaccine based on zona pellucida proteins from one species will be as efficacious as a vaccine based on the zona pellucida proteins of a different species. However, because porcine zonae pellucidae cross-react immunologically with the zonae pellucidae of a number of other mammals, it is believed that vaccines based on porcine zona pellucida proteins will be efficacious.
  • a contraceptive vaccine comprises at least one substantially pure recombinant porcine zona pellucida protein, or portion thereof.
  • One embodiment of the present invention is a contraceptive vaccine comprising one or more recombinant zona pellucida proteins, present in an amount effective to prevent conception.
  • a contraceptive vaccine of the present invention is preferably produced by culturing one or more hosts transformed with one or more zona pellucida DNA sequences in a manner that allows for production of one or more recombinant zona pellucida proteins, recovering said proteins, and combining one or more of the proteins to obtain a vaccine.
  • a preferred contraceptive vaccine is one containing more than one recombinant zona pellucida protein.
  • an advantage of using more than one recombinant zona pellucida protein is that a vaccinated animal will be exposed to a greater number of epitopes and will thus produce a group of antibodies capable of binding to a greater number of sites on the zona pellucida.
  • a contraceptive vaccine of the present invention can include, but is not limited to, at least a portion of one or more recombinant versions of natural porcine zona pellucida proteins selected from the group ZPl, ZP2, ZP3- alpha, ZP3-beta, ZP4, or mixtures thereof (i.e., proteins derived from recombinant DNA technology) .
  • a vaccine of the present invention comprises at least one protein encoded by at least a portion of a zona pellucida DNA sequence selected from the group ZPDS.2500, ZPDS.1711, ZPDS.1176, ZPDS.535, ZPDS.411, ZPDS.311, ZPDS.447, or a mixture thereof.
  • recombinant zona pellucida proteins contained in the contraceptive vaccine are glycosylated.
  • glycosylated proteins may elicit the production of antibodies that are better able to recognize and to bind to the highly glycosylated proteins on a vaccinated animal's zona pellucida because antibodies raised against glycosylated proteins will be able to recognize carbohydrate as well as protein determinants.
  • the contraceptive vaccine can also include an adjuvant or a carrier to improve its efficacy.
  • Adjuvants are typically substances that generally enhance the immune response of an animal to a specific antigen.
  • Suitable adjuvants include, but are not limited to, Freund's adjuvant, aluminum-based salts, calcium-based salts, silica, polynucleotides, saponin, coat proteins from viruses (such as feline panleukopenia virus) , bacterial-derived preparations (such as from Mycobacterium tuberculosis) , and proprietary adjuvants such as Titermax ® .
  • a preferred adjuvant of the present invention comprises aluminum hydroxide.
  • Carriers are typically compounds that increase the half-life of a vaccine in a vaccinated animal. Suitable carriers include, but are not limited to, polymeric controlled-release formulations, biodegradable implants, liposomes, bacteria (such as genetically-engineered M. tuberculosis) , viruses (such as genetically-engineered vaccinia virus) , oils, esters, and glycols.
  • One aspect of the present invention includes a process for preventing conception by administering an effective dose of a contraceptive vaccine of the present invention to prevent conception.
  • the ability of a contraceptive vaccine of the present invention to prevent conception can be reversible, or permanent, depending on the mode of adminis ⁇ tration.
  • the "mode of administration” includes the dose of the vaccine, the number and schedule of vaccinations, the age of the animal, and the route of administration (e.g., subcutaneous, intradermal, intravenous, nasal, oral, transdermal, and intramuscular.)
  • Animals which can be vaccinated according to the present invention include, but are not limited to, cats, dogs, humans, pigs, sheep, cattle, horses, burros, rabbits, elk, and deer.
  • an animal is administered a vaccine that is derived from a species other than itself. That is, preferably the zona pellucida proteins of the vaccine are proteins, or portions thereof, that are derived from a different species, and/or that are produced in a host of a different species.
  • animals are vaccinated to provide reversible contraception.
  • reversible contraception is a form of contraception from which an animal can recover (i.e., it is not permanent).
  • Reversible contraception can range in time from weeks to months to years depending on the species, vaccine dose and timing of administration.
  • the vaccinated animal will produce antibodies that will bind to its zona pellucida but will not sustain permanent damage to its ovaries or other components of the reproductive process.
  • the vaccine can be administered one or more times, preferably from about one to about three times, over from an about one-month to an about three-month period.
  • the vaccine dose (i.e., the amount of vaccine administered at one time) can range from about 25 ⁇ g to about 500 ⁇ g of recombinant protein. Preferably, a dose of from about 50 ⁇ g to about 100 ⁇ g of recombinant protein is administered.
  • Administration can be by a variety of modes including, but not limited to, subcutaneous, intradermal, intravenous, nasal, oral, transdermal, and intramuscular routes. Preferred modes of administration include subcutaneous and intramuscular routes.
  • Another aspect of the present invention includes a process for sterilizing an animal by administering to the animal an effective dose of a contraceptive vaccine of the present invention capable of rendering the animal sterile.
  • an effective dose to render an animal sterile is a dose which disrupts the ovaries to an extent that permanently prevents conception.
  • Contraceptive vaccines of the present invention capable of rendering an animal sterile can contain zona pellucida proteins, or portions thereof, that are recombinant, isolated from natural sources and/or chemically synthesized.
  • the vaccine comprises recombinant zona pellucida proteins. The inventor is unaware of the use of any zona pellucida protein to sterilize an animal.
  • An animal to be sterilized is preferably administered a vaccine that will stimulate both antibody and cell mediated immunity, particularly against a vaccinated animal's ovaries.
  • a vaccine is preferably administered one or more times before the animal reaches puberty, i.e., before the animal exhibits tolerance to proteins on its own zona pellucida.
  • Animals which can be rendered sterile include any mammal, such as, but not limited to cats, dogs, humans, pigs, sheep, cattle, horses, burros, rabbits, elk, and deer.
  • an animal such as a cat or dog, is first administered a contraceptive vaccine from about eight weeks to about sixteen weeks after birth, preferably from about ten weeks to about fourteen weeks after birth.
  • the contraceptive vaccine can be administered from about once to about three times over a period of from about six weeks to about ten weeks, preferably from about one time to about two times, over a period of from about two weeks to about three weeks.
  • the dose of the contraceptive vaccine preferably is such that only a few administrations are necessary. Preferred doses range from about 25 ⁇ g to about 500 ⁇ g and more preferably from about 50 ⁇ g to about 100 ⁇ g of protein.
  • a contraceptive vaccine that sterilizes an animal can be administered by a variety of modes including, but not limited to, subcutaneous, intradermal, intravenous, nasal, oral, transdermal, and intramuscular routes. Preferred modes of administration include subcutaneous and intramuscular routes.
  • Zona pellucida proteins comprising the vaccine can be produced by culturing hosts transformed with zona pellucida DNA sequences that encode at least a portion of a zona pellucida protein that is capable of rendering an animal sterile and by recovering proteins therefrom.
  • a host capable of glycosylating proteins preferably an insect cell, transformed with a zona pellucida DNA sequence such as ZPDS.1711, is cultured to produce a recombinant zona pellucida protein.
  • a vaccine comprising the recombinant protein, either alone, or in combination with at least one other recombinant zona pellucida protein, such as a recombinant zona pellucida protein encoded by ZPDS.311 and/or by ZPDS.447, is injected into an animal one or more times over a time period of from about three weeks to about eight weeks.
  • the efficacy of the vaccine to prevent conception can be tested in a variety of ways including, but not limited to, detection of zona pellucida-specific antibodies in the vaccinated animal's serum, examination of the vaccinated animal's ovaries, detection of ovulation, and mating of the vaccinated animal to a male.
  • a bacterial host preferably E. coli. transformed with a zona pellucida DNA sequence such as ZPDS.411, is cultured to produce a recombinant zona pellucida protein such as rZPP.137.
  • the recombinant protein is recovered and injected into an animal, preferably a rabbit, one or more times over a time period of about seven weeks.
  • a fusion protein containing the carboxyl terminus of S is one or more times over a time period of about seven weeks.
  • aponicum glutathione-S-transferase fused to rZPP.137 (GST-rZPP.137) is injected with an adjuvant subcutaneously and intramuscularly into a rabbit several times, with the injections being about one week apart. About one week after the final injection, serum is collected from the rabbit and analyzed for the presence of antibodies specific for porcine and/or canine zonae pellucidae. Ovaries from immunized rabbits are analyzed for abnormalities in follicular morphology and compared to ovaries from non-immunized rabbits. In yet another embodiment, a vaccine containing more than one porcine zona pellucida protein is used to sterilize an animal.
  • young rabbits preferably about five weeks old, were administered a vaccine comprising solubilized porcine zona pellucida several times over about six weeks.
  • vaccinated rabbits were essentially unable to ovulate.
  • rabbits immunized with a control protein one that does not induce contraception were able to ovulate and produce fetuses.
  • Example l Production of rabbit antiserum to solubilized porcine zonae pellucidae.
  • Porcine zonae pellucidae were isolated from pig ovaries using techniques similar to those described by Dunbar et al. (Biol. Reprod. 22, 941-954, 1980). The isolated zonae pellucidae were solubilized in 0.1 mM bicarbonate buffer at pH 9.0 by heating to 68°C for 20 min. Approximately 1000 zonae pellucidae (about 40 ⁇ g of protein) in 100 ⁇ l (microliters) were mixed with 100 ⁇ l of Freund's complete adjuvant and injected into multiple subcutaneous and intramuscular sites of a rabbit. Four, eight and twelve weeks later, the rabbit was boosted with the same dose of solubilized zonae pellucidae in Freund's incomplete adjuvant.
  • Serum was collected one week after the final immunization and was shown to contain antibodies specific for solubilized porcine zona pellucida by its ability to (a) react with intact porcine zonae pellucidae using an immunofluorescence assay, (b) react with zonae pellucidae present in pig ovary sections using an immunohistochemistry assay, and (c) react with solubilized zonae pellucidae using an immunoblot-based assay. This serum was subsequently used to screen a porcine ovary cDNA expression library.
  • Example 2 Isolation of clones containing zona pellucida DNA sequences.
  • the resultant cDNA was treated with EcoRI methylase to methylate EcoRI restriction sites within cDNA fragments.
  • EcoRI linkers were then added to the ends of the cDNA, and the linkered cDNA ligated into E. coli bacteriophage lambda phage gtll arms, using techniques described by Sambrook et al. (ibid.).
  • cDNA ligated into the lambda phage arms was packaged into phage particles using a Gigapack II Plus packaging extract, available from Stratagene of La Jolla, CA.
  • the resulting cDNA expression library was titered by plaque assay on E. coli Y1090 and stored in phage buffer (100 mM NaCl, 10 mM MgS0 4 , 50 mM Tris, pH 7.5, 0.01% gelatin) with chloroform at 4°C.
  • the agar surfaces were overlaid with nylon filters (e.g., Zeta-Probe which is available from Biorad of Richmond, CA) that had been soaked in 10 mM isopropyl-beta- D-thiogalactopyranoside (IPTG) and partially dried. Growth was continued overnight. Filters were marked with a 30 gauge needle at asymmetric points around their periphery, removed from the agar-containing plates, washed briefly at room temperature in TBST (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.1% Tween 20) and then submitted to two 30 min. washes in TBST at room temperature.
  • nylon filters e.g., Zeta-Probe which is available from Biorad of Richmond, CA
  • IPTG isopropyl-beta- D-thiogalactopyranoside
  • Washed filters were incubated in blocking buffer (TBST containing 10% bovine serum and 1.25% nonfat dry milk) for 3 to 4 hours, washed twice for 30 min. each in TBST, and incubated with an absorbed and diluted primary antibody solution for 3 to 4 hours, all at room temperature.
  • the absorbed and diluted primary antibody solution was prepared by mixing rabbit antiserum containing antibodies specific for a solubilized porcine zona pellucida (prepared as described in Example 1) with TBST containing 1% bovine serum and a 1:1000 dilution of Y1090 extract for 3 hours at 4°C, after which the antiserum was diluted to a final dilution of 1:500 in TBST.
  • NBT-BCIP substrate was prepared just before use in a buffer consisting of 100 mM Tris, pH 9.5, 100 mM NaCl, and 5 mM MgCl 2 .
  • phage were rescreened using the same protocol as described above until single plaque isolates were obtained that bound to rabbit antiserum containing antibodies specific for solubilized porcine zonae pellucidae. Approximately 1 in 300,000 phage screened contained a cDNA sequence encoding a protein that bound to antibodies specific for porcine zonae pellucidae. Single plaque isolates were amplified and DNA was purified therefrom to identify the size and sequence of the DNA insert. Phage DNA was digested with EcoRI. and the resulting cDNA insert was ligated into EcoRI-restricted Bluescript KS plasmids, available from Stratagene of La Jolla, CA.
  • Sequencing was performed using Sequenase kits, available from US Biochemical Corp., using techniques recommended by the manufacturer. Intelligenetics Inc. 's PC/GENE program and software written in-house were used to align data from DNA sequencing runs, to generate restriction maps, to translate DNA sequences into protein sequence, and to search for potential glycosylation sites.
  • ZPDS.2500 is composed of 3 EcoRI restriction fragments of about 535 bp, about 1176 bp, and about 800 bp, organized as diagrammed in Figure 1.
  • rZPP.305 is also shown.
  • rZPP.305 represents the putative carboxyl terminal portion of a porcine zona pellucida protein.
  • rZPP.305 exhibits a putative N-linked glycosylation site at amino acid 288.
  • Immunoprecipitation data (described in Example 5) suggest that rZPP.305 corresponds to a portion of porcine zona pellucida protein ZP2, which has a reported deglycosylated molecular weight of from about 52 kD to about 56 kD (Hedrick and Wardrip, 1987, ibid.), corresponding to about 460 amino acids.
  • the PALIGN program was used to compare protein homologies between rZPP.305 and published deduced protein sequences of other zona pellucida proteins.
  • rZPP.305 showed no similarity to mouse ZP2, mouse ZP3, hamster ZP3, human ZP3, or a rabbit 55-kD deglycosylated zona pellucida protein.
  • rZPP.305 was also compared to 20,024 other protein sequences in the Swiss-Prot data base; no similarities above 4% were observed.
  • ZPDS.311 A second single isolate was found to contain a cDNA fragment of approximately 311 bp in length, called ZPDS.311.
  • the DNA sequence of ZPDS.311 is presented in Figure 3 as is the deduced 103-amino acid sequence, called rZPP.103.
  • the protein sequence exhibits a putative N- linked glycosylation site at amino acid 43.
  • rZPP.103 does not share significant sequence homology with any other zona pellucida protein.
  • ZPDS.447 A third single isolate was found to contain a cDNA fragment of approximately 447 bp in length, called ZPDS.447.
  • the DNA sequence of ZPDS.447 is presented in Figure 4 as is the deduced 149-amino acid sequence, called rZPP.149.
  • the protein sequence exhibits putative N-linked glycosylation sites at amino acids 108 and 143. rZPP.149 does not share significant sequence homology with any other zona pellucida protein.
  • Example 3 Expression of a zona pellucida DNA sequence in bacterial cells.
  • ZPDS.411 A 411-bp HincII/EcoRI fragment of ZPDS.535, called ZPDS.411 (depicted in Figure 1) was ligated into the E. coli expression vector pGEX-2T (Smith and Johnson, 1988; available from Pharmacia) which had been digested with S al and EcoRI, using standard techniques as described in Sambrook et al. (ibid.). (Hindi and Smal both generate blunt ends.) The resultant recombinant molecule was called pGEX2T:ZPDS.411, and is shown in Figure 5.
  • ZPDS.411 was inserted into the pGEX-2T expression vector in such a way that cells transformed with the recombinant molecule pGEX2T:ZPDS.411 would express ZPDS.411 as a fusion protein containing the carboxyl terminus of Schistosoma iaponicum glutathione-S-transferase (GST) at the amino terminus and a recombinant zona pellucida protein of 137 amino acids (rZPP.137) encoded by ZPDS.411 at the carboxyl terminus, yielding GST-rZPP.137. Expression of GST-rZPP.137 was under the control of the IPTG-inducible tac promoter.
  • GST Schistosoma iaponicum glutathione-S-transferase
  • pGEX2T:ZPDS.411 was transformed into E. coli strain DH5-alpha to obtain transformed host E. coli pGEX2T:ZPDS.411, using techniques as described in SaitLbrook et al. (ibid.).
  • the transformed E. coli host was grown overnight in 50 ml of an aqueous fermentation medium comprising LB at 37°C, diluted 1:10 into 500 ml fresh LB at 37 ⁇ C and grown to mid-log phase (OD 600 of 0.6-1.0). IPTG was added to a final concentration of 1 mM and incubation continued for an additional 5 hr. Bacteria were collected by centrifugation and sonicated briefly.
  • the cell sonicate was mixed with an agarose resin to which glutathione was covalently attached (e.g., Glutathione Sepharose 4B from Pharmacia) in binding buffer (150 mM NaCl, 16 mM Na 2 HP0 4 , 4 mM NaH 2 P0 4 , pH 7.3) to allow the GST portion of the GST-rZPP.137 fusion protein to bind to the glutathione on the resin, whereas other materials in the suspension did not bind.
  • GST-rZPP.137 was subsequently eluted from the resin using a glutathione- containing solution (5 M glutathione, 50 mM Tris, pH 8.0) .
  • GST-rZPP.137 prepared in this manner is ready for use in a contraceptive vaccine.
  • Example 4 Expression of a zona pellucida DNA sequence in insect cells.
  • Zona pellucida DNA sequence ZPDS.1711 was first ligated into the multicloning site of Stratagene's pBLUESCRIPT II KS(-) plasmid vector to form PZP31.
  • PZP31 was submitted to a partial EcoRI digest and a Kpnl digest (there is a Kpnl site within the vector's multicloning site) .
  • ZPDS.1711 was mixed with both the BamHI/EcoRI oligoadapter
  • GTTTATACGGCCTAA that contains consensus baculovirus translation initiation sequences and a pVL1393 vector which had been cleaved with
  • pVL1393:ZPDS.1711 BamHI and Kpnl (see Figure 6) to obtain recombinant molecule pVL1393:ZPDS.1711.
  • ZPDS.1711 was inserted into pVL1393 such that expression of ZPDS.1711 was under the control of the regulatory region of the baculovirus polyhedrin gene and such that rZPP.305 does not contain any baculovirus amino acids.
  • pVL1393:ZPDS.1711 was introduced into Spodoptera frugiperda insect cells coincidentally with wild type baculovirus DNA, using techniques similar to those described by InVitrogen. Resulting recombinant baculovirus were identified by standard hybridization methods.
  • the recombinant baculovirus were shown by an immunoblotting experiment to encode a protein of the size expected for rZPP.305 that bound to antibodies specific for solubilized porcine zonae pellucidae (prepared as in Example 1) .
  • S_. frugiperda infected with the recombinant baculovirus i.e., transformed host S_. frugiperda pVL1393:ZPDS.1711
  • Grace's insect medium at about 27°C.
  • rZPP.305 protein was purified from infected cell lysates by differential centrifugation and conventional column chromatographic techniques or by polyacrylamide gel electrophoresis.
  • rZPP.305 prepared in this manner is ready for use in a contraceptive vaccine.
  • Example 5 Use of a recombinant zona pellucida protein as a vaccine.
  • GST-rZPP.137 produced as described in Example 4, was injected into a rabbit using the following protocol.
  • One mg of fusion protein in a volume of 500 ⁇ l was mixed with an equal volume of Freund's complete adjuvant and injected subcutaneously and intramuscularly.
  • Booster injections of the same dose in Freund's incomplete adjuvant were given every 7 days for 6 weeks.
  • Antiserum (GST-rZPP.137 antiserum) was collected one week after the final immunization and was shown to react with porcine zona pellucida by immunofluorescent staining of intact porcine zonae pellucidae.
  • the fluorescence observed using GST-rZPP.137 antiserum was not as strong as that seen with antiserum obtained from an animal immunized with solubilized porcine zonae pellucidae as described in Example 1 (pSZP antiserum) , but was much stronger than that seen with serum from a non-immunized animal (non-immune serum) .
  • Electrophoresis of complexes formed between 125 I-zona pellucida proteins and pSZP antiserum resolved as a broad band of radioactivity, indicative of overlapping zona pellucida glycoproteins.
  • a distinct, but much more narrow band was observed in the sample containing 125 I-zona pellucida proteins complexed with GST-rZPP.137 antiserum, indicating the antibodies likely reacted with a single class of zona pellucida glycoproteins.
  • Porcine zonae pellucidae were isolated and solubilized as described in Example 1.
  • a contraceptive vaccine dose comprising approximately 1000 zonae pellucidae (about 40 ⁇ g of protein) per 100 ⁇ l of Freund's complete adjuvant was prepared.
  • a vaccine dose was injected into each of five female rabbits, which were about five to about six weeks old, into multiple subcutaneous and intramuscular sites. Two and four weeks later, the rabbits were boosted with the same dose of solubilized zonae pellucidae in Freund's incomplete adjuvant.
  • Each of the ten rabbits was injected with 10 ⁇ g of gonadotropin-releasing hormone and artificially inseminated 134 days after the first immunization. Two weeks later, the rabbits were killed and analyzed for number of corpora lutea (# CLs, indicative of number of ovulations) and number of implantation sites (# Imp, indicative of number of fetuses) . The results are shown in Table 1. Table 1 Sterilization of Young Rabbits Control Rabbits Zona pellucida Treated Rabbits

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des vaccins contraceptifs à base de protéines zona pellucida, et des procédés d'utilisation de vaccins à base de protéines zona pellucida destinés à empêcher la conception chez des animaux. La contraception peut être soit réversible (c'est-à-dire temporaire) soit permanente (c'est-à-dire qu'elle rend l'animal stérile) selon le mode d'administration du vaccin. L'invention concerne des protéines zona pellucida porcines recombinées, des séquences d'ADN codant ces protéines, des méthodes de recombinaison permettant la production desdites protéines, et des procédés de production de vaccins comprenant une ou plusieurs de ces dernières. En outre, l'invention concerne des procédés d'utilisation d'une ou de plusieurs protéines zona pellucida afin d'induire la production d'anticorps spécifiques au zona pellucida chez un animal vacciné, et de détecter la présence d'anticorps spécifiques au zona pellucida dans un échantillon d'un liquide biologique.
PCT/US1993/001038 1992-02-04 1993-02-04 Composition et procede anticonceptionnels ou de sterilisation pour animaux WO1993014786A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83062792A 1992-02-04 1992-02-04
US830,627 1992-02-04

Publications (1)

Publication Number Publication Date
WO1993014786A1 true WO1993014786A1 (fr) 1993-08-05

Family

ID=25257349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001038 WO1993014786A1 (fr) 1992-02-04 1993-02-04 Composition et procede anticonceptionnels ou de sterilisation pour animaux

Country Status (2)

Country Link
AU (1) AU3611793A (fr)
WO (1) WO1993014786A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675269B2 (en) * 1992-11-09 1997-01-30 Zonagen, Inc. Materials and methods for immunocontraception
WO1999034825A1 (fr) * 1998-01-02 1999-07-15 The University Of Georgia Research Foundation, Inc. Vaccin anti-fecondite et mode d'utilisation
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
US7148021B2 (en) 2001-08-02 2006-12-12 Eastern Virginia Meical School Human zona pellucida proteins and methods of their use in diagnosing male infertility
US9034053B2 (en) 2004-02-25 2015-05-19 Femasys Inc. Methods and devices for conduit occlusion
US9220880B2 (en) 2004-02-25 2015-12-29 Femasys Inc. Methods and devices for delivery of compositions to conduits
US9238127B2 (en) 2004-02-25 2016-01-19 Femasys Inc. Methods and devices for delivering to conduit
US9402762B2 (en) 2004-02-25 2016-08-02 Femasys Inc. Methods and devices for conduit occlusion
US9554826B2 (en) 2008-10-03 2017-01-31 Femasys, Inc. Contrast agent injection system for sonographic imaging
US10070888B2 (en) 2008-10-03 2018-09-11 Femasys, Inc. Methods and devices for sonographic imaging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4996297A (en) * 1987-10-07 1991-02-26 Zonagen, Inc. Recombinantly expressed rabbit zona pellucida polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4996297A (en) * 1987-10-07 1991-02-26 Zonagen, Inc. Recombinantly expressed rabbit zona pellucida polypeptides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, Volume 8, issued 1989, A.G. SACCO et al., "Effect of Varying Dosages and Adjuvants on Antibody Response in Squirrel Monkeys (Saimiri Sciureus) Immunized with the Porcine Zona Pellucida, Mr=55,000 Glycoprotein (ZP3)", pages 1-8. *
FERTILITY AND STERILITY, Volume 52, Number 2, issued August 1989, B.S. DUNBAR et al., "Use of a Synthetic Peptide Adjuvant for the Immunization of Baboons with Denatured and Deglycosylated Pig Zona Pellucida Glycoproteins", pages 311-318. *
HOPPE-SEYLER'S ZEITSCHRIFT PHYSIOLOGICAL CHEMISTRY, Volume 386, issued April 1982, J. DIETL et al., "Solubilization of Four Porcine Zona Pellucida Antigens by Lithium 3,5-Diiodosalicylate", pages 381-386. *
J. FAHEY, "Manual of Clinical Laboratory Immunology", Published 1986, by AMERICAN SOCIETY FOR MICROBIOLOGY (D.C.). *
J. SAMBROOK et al., "Molecular Cloning, A Laboratory Manual", Published 1989, by COLD SPRING LABORATORY PRESS (N.Y.), pages 16-17.8. *
JOURNAL OF REPRODUCTION AND FERTILITY, Volume 76, issued 1986, A.G. SACCO et al., "Carbohydrate Influences the Immunogenic and Antigenic Characteristics of the ZP3 Macromolecule (MR 55 000) of the Pig Zona Pellucida", pages 575-585. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 78, issued 1981, T.P. HOPP et al., "Prediction of Protein Antigenic Determinants from Amino Acid Sequences", pages 3824-3828. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 80, isssued March 1983, R.A. YOUNG et al., "Efficient Isolation of Genes Using Antibody Probes", pages 1194-1198. *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675269B2 (en) * 1992-11-09 1997-01-30 Zonagen, Inc. Materials and methods for immunocontraception
WO1999034825A1 (fr) * 1998-01-02 1999-07-15 The University Of Georgia Research Foundation, Inc. Vaccin anti-fecondite et mode d'utilisation
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
US7148021B2 (en) 2001-08-02 2006-12-12 Eastern Virginia Meical School Human zona pellucida proteins and methods of their use in diagnosing male infertility
US9220880B2 (en) 2004-02-25 2015-12-29 Femasys Inc. Methods and devices for delivery of compositions to conduits
US10292732B2 (en) 2004-02-25 2019-05-21 Femasys, Inc. Methods and devices for conduit occlusion
US9238127B2 (en) 2004-02-25 2016-01-19 Femasys Inc. Methods and devices for delivering to conduit
US9308023B2 (en) 2004-02-25 2016-04-12 Femasys Inc. Methods and devices for conduit occlusion
US9402762B2 (en) 2004-02-25 2016-08-02 Femasys Inc. Methods and devices for conduit occlusion
US9034053B2 (en) 2004-02-25 2015-05-19 Femasys Inc. Methods and devices for conduit occlusion
US9839444B2 (en) 2004-02-25 2017-12-12 Femasys Inc. Methods and devices for conduit occlusion
US11779372B2 (en) 2004-02-25 2023-10-10 Femasys Inc. Methods and devices for conduit occlusion
US10111687B2 (en) 2004-02-25 2018-10-30 Femasys, Inc. Methods and devices for conduit occlusion
US9554826B2 (en) 2008-10-03 2017-01-31 Femasys, Inc. Contrast agent injection system for sonographic imaging
US10258375B2 (en) 2008-10-03 2019-04-16 Femasys, Inc. Methods and devices for sonographic imaging
US10172643B2 (en) 2008-10-03 2019-01-08 Femasys, Inc. Contrast agent generation and injection system for sonographic imaging
US11154326B2 (en) 2008-10-03 2021-10-26 Femasys Inc. Methods and devices for sonographic imaging
US11648033B2 (en) 2008-10-03 2023-05-16 Femasys Inc. Methods and devices for sonographic imaging
US10070888B2 (en) 2008-10-03 2018-09-11 Femasys, Inc. Methods and devices for sonographic imaging
US11980395B2 (en) 2008-10-03 2024-05-14 Femasys Inc. Methods and devices for sonographic imaging

Also Published As

Publication number Publication date
AU3611793A (en) 1993-09-01

Similar Documents

Publication Publication Date Title
TWI357906B (en) Neutralizing epitope-based growth enhancing vaccin
Neilson et al. cDNA cloning and characterization of a human sperm antigen (SPAG6) with homology to the product of the Chlamydomonas PF16 locus
EP0640133B1 (fr) Molecules d'adn recombinees codant des aminopeptidases et leur utilisation dans la preparation de vaccins contre les infections helminthiques
Wang et al. Immunisation of channel catfish, Ictalurus punctatus, with Ichthyophthirius multifiliis immobilisation antigens elicits serotype-specific protection
US5721348A (en) DNA encoding PH-20 proteins
JP2009077713A (ja) アイメリア・マキシマ（Ｅｉｍｅｒｉａｍａｘｉｍａ）の配偶子母細胞由来の組換え５６及び８２ｋＤａ各抗原をコードする核酸及びその使用
WO1993014786A1 (fr) Composition et procede anticonceptionnels ou de sterilisation pour animaux
RU2130072C1 (ru) Фрагмент днк, кодирующий иммуногенный поверхностный полипептид мерозоитов, иммуногенный полипептид (варианты) и способ его получения, рекомбинантная плазмидная днк и способ ее получения, способ получения рекомбинантного вируса вакцины, способ получения микроорганизма, вакцина против кокцидиоза птицы
US9102743B2 (en) Immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and uses thereof
EP1151118B1 (fr) Expression recombinante d'acides nucleiques heterologues dans un protozoaire
SA91110265B1 (ar) أمصال الكوكسيديوزيز المعادة الاتحاد5-7 مولدات أجسام مضادة سطحية لطفيل الايميريا
EP1035133B1 (fr) Protéines de fusion comprenant des supports capables d' induire une double réponse immunitaire
JPH025871A (ja) コクシジウム症ワクチンとして有用な組換え及び天然ａ、ｃ、ｆ及びｈ群アイメリア・テネラ免疫原
EP0290565B1 (fr) Vaccin contenant des antigenes de tiques
JP2000506381A (ja) マラリア原虫ｍｓｐ―１のｃ末端断片を含む組換えタンパク質
WO1997017444A2 (fr) Nouveaux recepteurs du sperme
RU2034457C1 (ru) Способ повышения продуктивности сельскохозяйственных животных и препарат для его осуществления
RU2205875C2 (ru) Очищенный антигенный полипептид, протективный против инфекции echinococcus granulosus, молекула днк, кодирующая указанный антигенный полипептид, препарат, содержащий указанный антигенный полипептид, вакцина, содержащая указанный антигенный полипептид или указанную молекулу днк
JP2003520594A (ja) 精子特異的タンパク質
US6514697B1 (en) Methods for detection of Crytosporidium species and isolates and for diagnosis of Cryptosporidium infections
JP2001523964A (ja) ダニ免疫を付与するための、およびダニ媒介性の疾患を防止するための、組成物および方法
US20230190905A1 (en) Transmission-blocking vaccine against babesia
CA1339466C (fr) Vaccin
CN117467018A (zh) 一种重组亚单位融合蛋白rEG95-Fc及其制备方法
GB2327346A (en) Parasite vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA